Macrogenics Inc (MGNX)
3.815
+0.04
(+1.19%)
USD |
NASDAQ |
Nov 14, 16:00
3.815
0.00 (0.00%)
After-Hours: 20:00
Macrogenics Research and Development Expense (Quarterly): 40.54M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 40.54M |
| June 30, 2024 | 51.73M |
| March 31, 2024 | 46.03M |
| December 31, 2023 | 47.35M |
| September 30, 2023 | 30.13M |
| June 30, 2023 | 43.23M |
| March 31, 2023 | 45.87M |
| December 31, 2022 | 45.65M |
| September 30, 2022 | 48.19M |
| June 30, 2022 | 51.74M |
| March 31, 2022 | 61.44M |
| December 31, 2021 | 55.85M |
| September 30, 2021 | 49.82M |
| June 30, 2021 | 55.78M |
| March 31, 2021 | 53.12M |
| December 31, 2020 | 42.30M |
| September 30, 2020 | 44.66M |
| June 30, 2020 | 57.35M |
| March 31, 2020 | 48.89M |
| December 31, 2019 | 51.96M |
| September 30, 2019 | 44.85M |
| June 30, 2019 | 51.44M |
| March 31, 2019 | 47.06M |
| December 31, 2018 | 46.92M |
| September 30, 2018 | 46.22M |
| Date | Value |
|---|---|
| June 30, 2018 | 52.01M |
| March 31, 2018 | 45.67M |
| December 31, 2017 | 38.99M |
| September 30, 2017 | 40.98M |
| June 30, 2017 | 34.46M |
| March 31, 2017 | 32.80M |
| December 31, 2016 | 31.11M |
| September 30, 2016 | 30.30M |
| June 30, 2016 | 33.34M |
| March 31, 2016 | 27.35M |
| December 31, 2015 | 30.04M |
| September 30, 2015 | 24.10M |
| June 30, 2015 | 22.66M |
| March 31, 2015 | 21.46M |
| December 31, 2014 | 19.65M |
| September 30, 2014 | 18.63M |
| June 30, 2014 | 17.34M |
| March 31, 2014 | 14.57M |
| December 31, 2013 | 14.35M |
| September 30, 2013 | 11.09M |
| June 30, 2013 | 11.05M |
| March 31, 2013 | 10.10M |
| December 31, 2012 | 8.508M |
| September 30, 2012 | 11.97M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
30.13M
Minimum
Sep 2023
61.44M
Maximum
Mar 2022
48.58M
Average
48.54M
Median
Research and Development Expense (Quarterly) Benchmarks
| KORU Medical Systems Inc | 1.134M |
| Apellis Pharmaceuticals Inc | 88.57M |
| NovaBay Pharmaceuticals Inc | 0.009M |
| Palatin Technologies Inc | 4.672M |
| iBio Inc | 1.14M |